Gut microbiota and cancer immunotherapy: mechanisms and modifications
DOI:
https://doi.org/10.54097/04m7xt20Keywords:
Cancer; immunotherapy; immunity.Abstract
Cancer is a global health issue, and the incidence and death rates are relatively high. In the aspect of cancer treatment, immunotherapy including immune checkpoint inhibitors and CAR-T cell therapy appear to be promising with less side effects compared to traditional methods such as chemotherapy and radiotherapy. However, the relatively low remission rate drives scientists to investigate the factors influencing the response to immunotherapy. A variety of microbes including bacteria, viruses and yeast colonize the gut, forming the gut microbiota. The gut microbiota play significant roles in infection diseases and autoimmune diseases because of the interplay between the intestinal microbiota and local mucosal immune system. Moreover, it has been found that there is a link between cancer treatment outcome and gut microbiota, indicating the great potential of modifying the gut microbiota as a treatment for boosting the therapy response rate. Unfortunately, the relationship between them remains unclear. Therefore, it is in an urgent need to further explore the mechanisms and functions of gut microbes in cancer immunity. This review introduces the impacts of gut microbiota on innate and adaptive immunity, the associations between therapy outcome and gut microbes, and discusses the modulation methods such as diet, fecal microbiota transplantation and probiotics.
Downloads
References
N. L.-N. Ting, H. C.-H. Lau, and J. Yu, “Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes,” Gut, vol. 71, no. 7, pp. 1412–1425, Jul. 2022, doi: 10.1136/gutjnl-2021-326264.
J. Wu, S. Wang, B. Zheng, X. Qiu, H. Wang, and L. Chen, “Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy,” Front Immunol, vol. 12, p. 669150, Jun. 2021, doi: 10.3389/fimmu.2021.669150.
L.-Y. Zhao et al., “Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications,” Sig Transduct Target Ther, vol. 8, no. 1, Art. no. 1, May 2023, doi: 10.1038/s41392-023-01406-7.
V. Matson, C. S. Chervin, and T. F. Gajewski, “Cancer and the Microbiome—Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy,” Gastroenterology, vol. 160, no. 2, pp. 600–613, Jan. 2021, doi: 10.1053/j.gastro.2020.11.041.
X. Wang and S. Geng, “Diet-gut microbial interactions influence cancer immunotherapy,” Front Oncol, vol. 13, p. 1138362, Mar. 2023, doi: 10.3389/fonc.2023.1138362.
Z. Peng et al., “The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer,” Cancer Immunology Research, vol. 8, no. 10, pp. 1251–1261, Oct. 2020, doi: 10.1158/2326-6066.CIR-19-1014.
R. Jain et al., “Dissecting the Impact of the Gut Microbiome on Cancer Immunotherapy,” Res Sq, p. rs.3.rs-3647386, Nov. 2023, doi: 10.21203/rs.3.rs-3647386/v1.
A. Singh, S. G. Alexander, and S. Martin, “Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy,” Front Immunol, vol. 14, p. 1114499, May 2023, doi: 10.3389/fimmu.2023.1114499.
A. E. Frankel et al., “Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota,” Integr Cancer Ther, vol. 18, p. 1534735419846379, Apr. 2019, doi: 10.1177/1534735419846379.
X. Li, S. Zhang, G. Guo, J. Han, and J. Yu, “Gut microbiome in modulating immune checkpoint inhibitors,” eBioMedicine, vol. 82, p. 104163, Jul. 2022, doi: 10.1016/j.ebiom.2022.104163.
M. R. Fernandes, P. Aggarwal, R. G. F. Costa, A. M. Cole, and G. Trinchieri, “Targeting the gut microbiota for cancer therapy,” Nat Rev Cancer, vol. 22, no. 12, Art. no. 12, Dec. 2022, doi: 10.1038/s41568-022-00513-x.
S. Asokan, N. Cullin, C. K. Stein-Thoeringer, and E. Elinav, “CAR-T Cell Therapy and the Gut Microbiota,” Cancers (Basel), vol. 15, no. 3, p. 794, Jan. 2023, doi: 10.3390/cancers15030794.
D. Davar et al., “Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients,” Science, vol. 371, no. 6529, pp. 595–602, Feb. 2021, doi: 10.1126/science.abf3363.
M. Szczyrek, P. Bitkowska, P. Chunowski, P. Czuchryta, P. Krawczyk, and J. Milanowski, “Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review,” Nutrients, vol. 13, no. 7, p. 2217, Jun. 2021, doi: 10.3390/nu13072217.
M. Smith et al., “Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy,” Nat Med, vol. 28, no. 4, pp. 713–723, Apr. 2022, doi: 10.1038/s41591-022-01702-9.
Y. Hu et al., “CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies,” Nat Commun, vol. 13, p. 5313, Sep. 2022, doi: 10.1038/s41467-022-32960-3.
Y. Xin, C.-G. Liu, D. Zang, and J. Chen, “Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer,” Front Immunol, vol. 15, p. 1343450, Feb. 2024, doi: 10.3389/fimmu.2024.1343450.
“Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors | Cancer Chemotherapy and Pharmacology.” Accessed: Mar. 06, 2024. [Online]. Available: https://link.springer.com/article/10.1007/s00280-019-03993-1
Y. Zheng et al., “Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma,” J Immunother Cancer, vol. 7, p. 193, Jul. 2019, doi: 10.1186/s40425-019-0650-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
